摘要
他克莫司(Tacrolimus, TAC)作为临床上用于器官移植术后抗免疫排斥治疗的一线用药,由于其存在治疗窗窄,血药浓度个体差异大等特点往往给移植患者的器官存活造成很大的影响。药物基因多态性已被证实为导致他克莫司个体间药物代谢动力学特征差异性的主要原因之一,因此本文通过对影响肾移植患者体内他克莫司代谢的相关基因多态性的研究进展进行综述,以为促进TAC在肾移植患者中的临床个体化应用提供参考。
Tacrolimus(TAC) is clinically used as a first-line drug for the treatment of anti-immune rejection after organ transplantation. Due to its narrow therapeutic window and large individual differences in blood drug concentration, it often affects the organ survival of transplant patients. great impact. Pharmacogenetic polymorphisms have been confirmed to be one of the main reasons for the differences in the pharmacokinetic characteristics of tacrolimus among individuals. Therefore, this paper analyzes the related single nucleotide polymorphism affecting the metabolism of TAC in kidney transplant patients. The research progress is reviewed to provide some references to promote the individualized clinical administration of tacrolimus in kidney transplant patients.
作者
杨金伟
宋沧桑
李兴德
张函舒
王国徽
宋文彬
YANG Jin-wei;SONG Cang-sang;LI Xing-de;ZHANG Han-shu;WANG Guo-hui;SONG Wen-bin(Affiliated Galmette Hospital of Kunming Medical University,Yunnan Kunming 650000,China;Department of Pharmacy,The First people′s Hospital of Kunming,Yunnan Kunming 650000,China)
出处
《中国药物评价》
2023年第1期23-28,共6页
Chinese Journal of Drug Evaluation
基金
云南省器官移植临床医学中心开放课题基金(No.2020SYZ-Z-023)
云南省器官移植临床医学中心开放课题基金(No.2020SYZ-Z-031)
云南省卫生健康委员会医学领军人才培养计划项目(No.L-2018012)
昆明市卫生科技人才培养项目(No.2018-SW(省)-05)。
关键词
他克莫司
肾移植
单核苷酸多态性
药动学
药效学
Tacrolimus
Kidney Transplantation
Single Nucleotide Polymorphism
Pharmacokinetics
Pharmacodynamics
